Discovery and Early Development of AVI-7537 and AVI-7288 for the Treatment of Ebola Virus and Marburg Virus Infections

There are no currently approved treatments for filovirus infections. In this study we report the discovery process which led to the development of antisense Phosphorodiamidate Morpholino Oligomers (PMOs) AVI-6002 (composed of AVI-7357 and AVI-7539) and AVI-6003 (composed of AVI-7287 and AVI-7288) targeting Ebola virus and Marburg virus respectively. The discovery process involved identification of optimal transcript binding sites for PMO based RNA-therapeutics followed by screening for effective viral gene target in mouse and guinea pig models utilizing adapted viral isolates. An evolution of chemical modifications were tested, beginning with simple Phosphorodiamidate Morpholino Oligomers (PMO) transitioning to cell penetrating peptide conjugated PMOs (PPMO) and ending with PMOplus containing a limited number of positively charged linkages in the PMO structure. The initial lead compounds were combinations of two agents targeting separate genes. In the final analysis, a single agent for treatment of each virus was selected, AVI-7537 targeting the VP24 gene of Ebola virus and AVI-7288 targeting NP of Marburg virus, and are now progressing into late stage clinical development as the optimal therapeutic candidates.

• Publication year

  2012

• Venue

  Viruses

• Publication date

  2012-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3390/v4112806PMID 23202506PMCID 3509674
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study

  2012cited by this paper
• Protective Efficacy of Neutralizing Monoclonal Antibodies in a Nonhuman Primate Model of Ebola Hemorrhagic Fever

  2012cited by this paper
• Nonhuman primates as models for the discovery and development of ebolavirus therapeutics

  2011cited by this paper
• Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant

  2011cited by this paper
• Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study

  2011cited by this paper
• Basic clinical and laboratory features of filoviral hemorrhagic fever.

  2011influential reference
• Advanced antisense therapies for postexposure protection against lethal filovirus infections

  2010cited by this paper
• Antisense phosphorodiamidate morpholino oligomers targeted to an essential gene inhibit Burkholderia cepacia complex.

  2010cited by this paper
• Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study

  2010cited by this paper
• Inhibition of Intracellular Growth of Salmonella enterica Serovar Typhimurium in Tissue Culture by Antisense Peptide-Phosphorodiamidate Morpholino Oligomer

  2009cited by this paper
• Chemical Modifications of Antisense Morpholino Oligomers Enhance Their Efficacy against Ebola Virus Infection

  2009cited by this paper
• Activation of Transgene-specific T Cells Following Lentivirus-mediated Gene Delivery to Mouse Lung

  2009cited by this paper
• Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study

  2009cited by this paper
• Inhibition of alphavirus infection in cell culture and in mice with antisense morpholino oligomers

  2008cited by this paper
• Functional CD8+ T Cell Responses in Lethal Ebola Virus Infection1

  2008cited by this paper
• Virus-specific antiviral treatment for controlling severe and fatal outbreaks of feline calicivirus infection.

  2008cited by this paper
• Treatment of AG129 mice with antisense morpholino oligomers increases survival time following challenge with dengue 2 virus

  2008cited by this paper
• Variations in Amino Acid Composition of Antisense Peptide-Phosphorodiamidate Morpholino Oligomer Affect Potency against Escherichia coli In Vitro and In Vivo

  2008cited by this paper
• A Morpholino Oligomer Targeting Highly Conserved Internal Ribosome Entry Site Sequence Is Able To Inhibit Multiple Species of Picornavirus

  2008cited by this paper
• Inhibition of influenza A H3N8 virus infections in mice by morpholino oligomers

  2008cited by this paper
• Morpholino oligomers targeting the PB1 and NP genes enhance the survival of mice infected with highly pathogenic influenza A H7N7 virus.

  2008cited by this paper
• Arginine-rich cell-penetrating peptides facilitate delivery of antisense oligomers into murine leukocytes and alter pre-mRNA splicing.

  2007cited by this paper
• Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever.

  2007cited by this paper
• Cell-penetrating peptides as transporters for morpholino oligomers: effects of amino acid composition on intracellular delivery and cytotoxicity

  2007cited by this paper
• Hormonal and nutritional regulation of alternative CD36 transcripts in rat liver – a role for growth hormone in alternative exon usage

  2007cited by this paper
• Cell penetrating peptide conjugates of steric block oligonucleotides

  2007cited by this paper
• Stability of cell-penetrating peptide-morpholino oligomer conjugates in human serum and in cells.

  2007cited by this paper
• Inhibition of Coxsackievirus B3 in Cell Cultures and in Mice by Peptide-Conjugated Morpholino Oligomers Targeting the Internal Ribosome Entry Site

  2006cited by this paper
• Vectorization of morpholino oligomers by the (R-Ahx-R)4 peptide allows efficient splicing correction in the absence of endosomolytic agents.

  2006cited by this paper
• VP35 Knockdown Inhibits Ebola Virus Amplification and Protects against Lethal Infection in Mice

  2006cited by this paper
• A DNA Vaccine for Ebola Virus Is Safe and Immunogenic in a Phase I Clinical Trial

  2006influential reference
• Gene-Specific Countermeasures against Ebola Virus Based on Antisense Phosphorodiamidate Morpholino Oligomers

  2006cited by this paper
• Gene-Specific Effects of Antisense Phosphorodiamidate Morpholino Oligomer-Peptide Conjugates on Escherichia coli and Salmonella enterica Serovar Typhimurium in Pure Culture and in Tissue Culture

  2006cited by this paper
• Antisense peptide-phosphorodiamidate morpholino oligomer conjugate: dose-response in mice infected with Escherichia coli.

  2006cited by this paper
• Induction of revertant fibres in the mdx Mouse using antisense oligonucleotides

  2005cited by this paper
• Antisense phosphorodiamidate morpholino oligomer inhibits viability of Escherichia coli in pure culture and in mouse peritonitis.

  2005cited by this paper
• Antisense Phosphorodiamidate Morpholino Oligomer Length and Target Position Effects on Gene-Specific Inhibition in Escherichia coli

  2005cited by this paper
• Cellular uptake of antisense morpholino oligomers conjugated to arginine-rich peptides.

  2004cited by this paper
• Peroxisome proliferator-activated receptor γ and cancers

  2003cited by this paper
• Efficacy of antisense morpholino oligomer targeted to c-myc in prostate cancer xenograft murine model and a Phase I safety study in humans.

  2003cited by this paper
• Resistance to chemotherapeutic drugs overcome by c-Myc inhibition in a Lewis lung carcinoma murine model

  2003cited by this paper
• Inhibition of Gene Expression in Escherichia coli by Antisense Phosphorodiamidate Morpholino Oligomers

  2003cited by this paper
• Peroxisome proliferator-activated receptor gamma and cancers.

  2003cited by this paper
• HIV Tat Peptide Enhances Cellular Delivery of Antisense Morpholino Oligomers

  2003cited by this paper
• Intramural coronary delivery of advanced antisense oligonucleotides reduces neointimal formation in the porcine stent restenosis model.

  2002cited by this paper
• c-myc antisense oligonucleotide treatment ameliorates murine ARPKD.

  2002cited by this paper
• Desacetyl-diltiazem displays severalfold higher affinity to CYP2D6 compared with CYP3A4.

  2002cited by this paper
• Inhibition of human chorionic gonadotropin β‐subunit modulates the mitogenic effect of c‐myc in human prostate cancer cells

  2002cited by this paper
• Phosphorodiamidate morpholino antisense oligomers inhibit expression of human cytochrome P450 3A4 and alter selected drug metabolism.

  2002cited by this paper
• Transdermal Use of Phosphorodiamidate Morpholino Oligomer AVI-4472 Inhibits Cytochrome P450 3A2 Activity in Male Rats

  2002cited by this paper
• Inhibition of Vesivirus Infections in Mammalian Tissue Culture with Antisense Morpholino Oligomers

  2001cited by this paper
• Phosphorodiamidate morpholino oligomers: favorable properties for sequence-specific gene inactivation.

  2001cited by this paper
• Antiproliferative Effects of Steric Blocking Phosphorodiamidate Morpholino Antisense Agents Directed against c-myc

  2000cited by this paper
• Morpholino Antisense Oligomers: Design, Preparation, and Properties

  1997cited by this paper
• A Specificity Comparison of Four Antisense Types: Morpholino, 2′-O-Methyl RNA, DNA, and Phosphorothioate DNA

  1997cited by this paper
• Resistance of Morpholino Phosphorodiamidate Oligomers to Enzymatic Degradation

  1996cited by this paper
• Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses.

  1996cited by this paper
• Competing Interests: GJN:

  year unknowncited by this paper

• Development of a two-dimensional liquid chromatography/mass spectrometry workflow for characterization of phosphorodiamidate morpholino oligomers.

  2025cites this paper
• Emerging Strategies and Progress in the Medical Management of Marburg Virus Disease

  2025cites this paper
• Overview of Marburg Viral Disease

  2025cites this paper
• Increasing Occurrence of Marburg Virus Outbreaks in Africa: Risk Assessment for Public Health

  2025cites this paper
• Sequencing of Phosphorodiamidate Morpholino Oligomers by Hydrophilic Interaction Chromatography Coupled to Tandem Mass Spectrometry

  2024cites this paper
• Recent Advances in Therapeutic Approaches Against Ebola Virus Infection.

  2024cites this paper
• Cell-Penetrating Peptides in infection and immunization.

  2024cites this paper
• Emerging and reemerging infectious diseases: global trends and new strategies for their prevention and control

  2024cites this paper
• Therapeutic phosphorodiamidate morpholino oligonucleotides: Physical properties, solution structures, and folding thermodynamics

  2023cites this paper
• Small-molecule oligonucleotides as smart modality for antiviral therapy: a medicinal chemistry perspective.

  2023cites this paper
• Antisense oligonucleotides: a promising therapeutic option against infectious diseases

  2023cites this paper
• Marburg virus disease treatments and vaccines: recent gaps and implications

  2023cites this paper
• A bibliometric study on Marburg virus research with prevention and control strategies

  2023cites this paper
• History and impact of the mouse-adapted Ebola virus model.

  2022cites this paper
• Leveraging the therapeutic, biological, and self-assembling potential of peptides for the treatment of viral infections.

  2022cites this paper
• Small Drugs, Huge Impact: The Extraordinary Impact of Antisense Oligonucleotides in Research and Drug Development

  2022cites this paper
• Cynarin blocks Ebola virus replication by counteracting VP35 inhibition of interferon-beta production.

  2022cites this paper
• Automated Fast Flow Peptide Synthesis

  2021cites this paper
• Contemplating Potential Chemical Therapeutic Options to Combat Marburg Virus

  2021cites this paper
• Pharmacology and toxicology of eteplirsen and SRP-5051 for DMD exon 51 skipping: an update

  2021cites this paper
• Inhibitors of Ebolavirus targeting innate immune evasion

  2021cites this paper
• Targeting Ebola virus replication through pharmaceutical intervention

  2021cites this paper
• Ebola Virus and Its Immunopathogenesis - A Review

  2020cites this paper
• Synthesis and Identification of Novel Arylnaphthalene V-ATPase Inhibitors as Selective Anti-Filoviral Agents

  2020cites this paper
• Fully automated fast-flow synthesis of antisense phosphorodiamidate morpholino oligomers

  2020cites this paper
• Automated Fast-Flow Synthesis of Antisense Phosphorodiamidate Morpholino Oligomers

  2020cites this paper
• Marburg virus disease: A summary for clinicians

  2020cites this paper
• Combating biothreat pathogens: ongoing efforts for countermeasure development and unique challenges

  2020cites this paper
• Peptide-Conjugated Phosphorodiamidate Morpholino Oligomers for In Situ Live-Cell Molecular Imaging of Dengue Virus Replication

  2020cites this paper
• Ebola virus disease: An emerging and re-emerging viral threat.

  2019cites this paper
• Insights into Ebola Virus VP35 and VP24 Interferon inhibitory functions and their initial exploitation as drug targets

  2019cites this paper
• Second generation of diazachrysenes: Protection of Ebola virus infected mice and mechanism of action.

  2019cites this paper
• Ebola Virus Disease

  2019cites this paper
• Epidemiological Trends and Current Challenges in Ebola: Pathogen Biology, Drug Targets, and Therapeutic Strategies

  2019cites this paper
• Next generation agents (synthetic agents): Emerging threats and challenges in detection, protection, and decontamination

  2019cites this paper
• Alternative splicing of the vitamin D receptor modulates target gene expression and promotes ligand‐independent functions

  2019cites this paper
• Relevance of Ebola virus VP35 homo-dimerization on the type I interferon cascade inhibition

  2019cites this paper
• Therapeutic strategies to target the Ebola virus life cycle

  2019cites this paper
• Classes and Applications of Cell-Penetrating Peptides

  2019cites this paper
• Antisense Phosphorodiamidate Morpholino Oligomers as Novel Antiviral Compounds

  2018influential citation
• Advances in Designing and Developing Vaccines, Drugs, and Therapies to Counter Ebola Virus

  2018cites this paper
• Prologue

  2018cites this paper
• Development of Locked Nucleic Acid Antisense Oligonucleotides Targeting Ebola Viral Proteins and Host Factor Niemann-Pick C1

  2018cites this paper
• Molecular Basis of Resilience

  2018cites this paper
• Interference of DNAJB6/MRJ Isoform Switch by Morpholino Inhibits Replication of HIV-1 and RSV

  2018cites this paper
• Anti-Ebola therapies based on monoclonal antibodies: current state and challenges ahead

  2017cites this paper
• Ebola Virus Infection: a review on the pharmacokinetic and pharmacodynamic properties of drugs considered for testing in human efficacy trials

  2017influential citation
• Discovering Drugs for the Treatment of Ebola Virus

  2017cites this paper
• Clinical potential of oligonucleotide-based therapeutics in the respiratory system.

  2017cites this paper
• Macrocyclic peptide inhibitors for the protein-protein interaction of Zaire Ebola virus protein 24 and karyopherin alpha 5.

  2017cites this paper
• Will There Be a Cure for Ebola?

  2017cites this paper
• The Pathogenesis of Ebola Virus Disease.

  2017cites this paper
• Ebola Virus Disease: Biology, Diagnosis, Treatment and Prevention of Epidemics

  2017cites this paper
• Review of Current Non-Vaccine Based Approaches for the Prevention and Treatment of Flaviviral Diseases

  2017cites this paper
• Applications of antisense oligonucleotides in designing a therapy for spinal muscular atrophy

  2017cites this paper
• Le virus Ebola : impact de l’épidémie de 2014-2016 sur la recherche

  2017cites this paper
• Ebola virus – epidemiology, diagnosis, and control: threat to humans, lessons learnt, and preparedness plans – an update on its 40 year's journey

  2017cites this paper
• Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses

  2017cites this paper
• Assessing Antiviral Countermeasures Using Mouse Models of Ebolavirus Infection.

  2017cites this paper
• From Cryptic Toward Canonical Pre-mRNA Splicing in Pompe Disease: a Pipeline for the Development of Antisense Oligonucleotides

  2016cites this paper
• The Drug Targets and Antiviral Molecules for Treatment of Ebola Virus Infection.

  2016cites this paper
• Neglected filoviruses.

  2016influential citation
• Hemorrhagic Fever Viruses

  2016cites this paper
• Modified Antisense Oligonucleotides and Their Analogs in Therapy of Neuromuscular Diseases

  2016cites this paper
• Le virus Ebola, de sa découverte au développement d'une vaccination efficace

  2016influential citation
• Treatment of Ebola Virus Disease: Therapeutic Agents

  2016cites this paper
• Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials

  2016cites this paper
• Ebola virus - from neglected threat to global emergency state.

  2016cites this paper
• Morpholino antisense oligo inhibits trans-splicing of pre-inositol 1,4,5-trisphosphate receptor mRNA of Trypanosoma cruzi and suppresses parasite growth and infectivity.

  2016cites this paper
• Past, Present and Future about Ebola Virus Diseases: An Updated Review

  2016cites this paper
• Pre-mRNA Splicing in Pompe Disease : prospects for antisense therapy

  2016cites this paper
• Maladie à virus Ebola : actualités thérapeutiques

  2016cites this paper
• Ebola vaccine, therapeutics, and diagnostics.

  2016cites this paper
• Situación actual del tratamiento farmacologico frente a la enfermedad causada por el virus Ébola

  2016cites this paper
• Structure Activity Study of Clinically Observed Adverse Events and Oligomer Chemistry

  2016cites this paper
• Prediction of Epitope-Based Peptides for Vaccine Development from Coat Proteins GP2 and VP24 of Ebola Virus Using Immunoinformatics

  2016cites this paper
• Delayed Time-to-Treatment of an Antisense Morpholino Oligomer Is Effective against Lethal Marburg Virus Infection in Cynomolgus Macaques

  2016cites this paper
• Development of Small‐Molecule Antivirals for Ebola

  2015cites this paper
• Amiodarone and metabolite MDEA inhibit Ebola virus infection by interfering with the viral entry process

  2015cites this paper
• Antiviral Medications and Plasma Efficacy in Treating Ebola Patients: A Systematic Review

  2015cites this paper
• CONSIDERING THE MALARIA IS ESSENTIAL IN A PATIENT WITH SUSPECTED EBOLA: CASE REPORT

  2015cites this paper
• Ebola virus disease: Basics the medical specialist should know

  2015cites this paper
• Exploring the Pathophysiological Concepts of Ebola Virus

  2015cites this paper
• Delivery of therapeutic oligonucleotides with cell penetrating peptides☆

  2015cites this paper
• Application of modified antisense oligonucleotides and siRNAs as antiviral drugs.

  2015cites this paper
• Ebola: Implications and Perspectives.

  2015cites this paper
• Ebola virus outbreak, updates on current therapeutic strategies

  2015cites this paper
• Treatment of Ebola Virus Disease

  2015cites this paper
• Mechanisms of Immunity in Post-Exposure Vaccination against Ebola Virus Infection

  2015cites this paper
• DNA and RNA derivatives to optimize distribution and delivery.

  2015cites this paper
• A Single Phosphorodiamidate Morpholino Oligomer Targeting VP24 Protects Rhesus Monkeys against Lethal Ebola Virus Infection

  2015cites this paper
• Filoviruses: One of These Things is (not) Like the Other

  2015cites this paper
• Potential and Emerging Treatment Options for Ebola Virus Disease

  2015cites this paper
• Emergence of Ebola Virus Escape Variants in Infected Nonhuman Primates Treated with the MB-003 Antibody Cocktail.

  2015cites this paper
• Ebola Virus Infection: Overview and Update on Prevention and Treatment

  2015influential citation
• Translational Research in Acute Lung Injury and Pulmonary Fibrosis Ebola : history , treatment , and lessons from a new emerging pathogen

  2015cites this paper
• Improving attrition rates in Ebola virus drug discovery

  2015cites this paper
• Ebola: history, treatment, and lessons from a new emerging pathogen.

  2015cites this paper
• Therapeutics for postexposure treatment of Ebola virus infection.

  2015cites this paper
• Ebola virus: understanding the 2014 outbreak.

  2015cites this paper